NCT00574379View on ClinicalTrials.gov

Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR

PHASE2CompletedINTERVENTIONAL
Enrollment

805

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Seasonal Allergic RhinitisHay FeverAllergic ConjunctivitisHypersensitivity
Interventions
DRUG

Bilastine

Bilastine 10 or 20mg, once or twice daily for 14 days. Tablets

DRUG

Placebo

Placebo tablets twice daily for 14 days

Trial Locations (13)

73104

Oklahoma Allergy and Asthma Clinic, Oklahoma City

76708

Allergy & Asthma Care of Waco, Waco

76712

Allergy Asthma Research Institute, Waco

78229

Biogenics Research Institute, San Antonio

DGD Research, San Antonio

Diagnostics Research Group, San Antonio

Southwest Allergy and Asthma Centre, San Antonio

Sylvana Research Associates, San Antonio

78233

Live Oak Allergy and Asthma, San Antonio

78704

MetaClin Research Inc., Austin

78750

Austin Clinical Research, Austin

78759

Lovelace Scientific Resources, Austin

78028-6071

Kerrville Research Associates, Kerrville

Sponsors

Lead Sponsor

Faes Farma, S.A.
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Allied Research International

INDUSTRY

lead

Faes Farma, S.A.

INDUSTRY